natgillin/translations-raw huggingface dataset:
The EGFR-homing vector for use according to claim 1 or any one of claims 3 to 11 or the pharmaceutical composition for use according to any one of claims 2 to 11, wherein said cancer is selected from non-small-cell-lung-carcinoma, breast cancer, glioblastoma, head and neck squamous cell carcinoma, colorectal cancer, adenocarcinoma, ovary cancer, bladder cancer or prostate cancer, or metastases thereof. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se koristi u liječenju karcinoma odabranog između ne-staničnog karcinoma dojke, karcinoma dojke, glioblastoma, karcinoma pločastih stanica glave i vrata, kolorektalnog karcinoma, adenokarcinoma, karcinoma jajnika, karcinoma mokraćnog mjehura ili karcinoma prostate i njihove metastaze.
The method of claim 6, further comprising: after said puncturing the lid (3), measuring a temperature of contents of the cartridge (1; 50); and heating a liquid to be provided into the cartridge (1; 50) to a temperature based at least in part on the temperature of the contents of the cartridge (1; 50). 
Metoda iz zahtjeva 6, naznačena time, da nadalje obuhvaća: nakon navedenog probijanja poklopca (3), mjerenja temperature sadržaja uloška (1; 50); 1 zagrijavanje tekućine koja se daje u uložak (1; 50) na temperaturu koja se dijelom temelji barem na temperaturi sadržaja uloška (1; 50).
reacting said purified Compound 8 with a secondary amine and a carboxylic acid in a first solvent to produce Compound 10 . The process of claim 2, wherein: 
(d) reakciji navedenog pročišćenog Spoja 8 sekundarnim aminom i karboksilnom kiselinom u prvom otapalu kako bi se dobilo Spoj 10: i
a pad layer, wherein said pad layer is attached to said base layer. 
pokrovni sloj (11), gdje je navedeni pokrovni sloj pričvršćen na navedeni osnovni materijal (6).
A compound of Formula Ia: or a pharmaceutically acceptable salt thereof in combination with vemurafenib or a pharmaceutically acceptable salt thereof, for use in the therapeutic treatment of metastatic or unresectable melanoma. 
Spoj, naznačen time, da ima formulu Ia: [image] te se u kombinaciji s abirateronom upotrebljava u terapeutskom postupku liječenja hiperproliferativnog poremećaja, pri čemu se kod hiperproliferativnog poremećaja radi o raku prostate.
a step of positioning said reel (5) mounted on a metalwork support saddle, in particular by means of a crane, between said spread shoulders (4); 
- < korak pozicioniranja spomenutog kalema (5) montiranog na čvrstom metalnom nosivom sjedištu, prvenstveno pomoću dizalice, između spomenutih raširenih oslonaca (4);
determining whether the compound increases a blood GLP-1 level in the mammal; wherein the ability of the test compound to increase a blood GLP-1 level in the mammal is indicative of the test compound being a GLP-1 secretagogue or a compound useful for treating or preventing a condition ameliorated by increasing a blood GLP-1 level. 
(o) određivanje nivoa GLP-1 u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen spoj koji stimulira funkcionalnost receptora iz (b); pri čemu je sposobnost test spoja da poveća nivo GLP-I u krvi u sisavcu nadalje indikativna da je test spoj GLP-I sekretogog.
example, TBDMS or TES P2 hydroxyl protecting group such as a silyl protecting group, for 
P, hidroksilna zaštitna skupina kao što je silil zaštitna skupina, na primjer, TES P;
The present invention also relates to a method of preparation of the docosahexaenoic acid ester according to the present invention, in particular the pyridin-3-ylmethyl docosahexaeneoate (1) according to the present invention, by transesterification of docosahexaenoic acid ethyl ester with an alcohol chosen among the group comprised of nicotinyl alcohol, panthenol, isosorbide, isosorbide mononitrate and inositol, advantageously with nicotinyl alcohol. 
H ono, Ester dokosaheksanske kiseline, naznačen time da je s pantenolom. Metoda priprave estera dokosaheksanske kiseline prema patentnom zahtjevu 1 ili 2, naznačena time da obuhvaća transesterifikaciju etilnog estera dokosaheksanske kiseline s alkoholom odabranim iz sljedeće skupine: pantenol, izosorbid te izosorbid-mononitrat,
DHFR enzyme was purified from rat livers and assays of enzyme activity were performed at 37 °C by monitoring changes in UV absorbance at 340 nm of a solution containing 50 mM N -tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (pH 7.0), 1 mM EDTA, 75 µM 2-mercaptoethanol, 0.1 % bovine serum albumin, 20 µM dihydrofolate, and 100 µM NADPH. 
Ispitivanja enzimske aktivnosti provedena su pri 37 *C praćenjem promjena u UV apsorbanciji pri 340 nm otopine koja sadrži 50 mM N-tris(hidroksimetil)metil-2-aminoctansulfonske kiseline (pH 7,0), 1 mM EDTA, 75 uM 2-merkaptoctanola, 0,1 % albumina goveđeg seruma, 20 UM dihidrofolata, i 100 uM NADPH.
The stationary modular transceiver device according to claim 8 wherein the at least one transmit-receive antenna is a WiFi antenna or a router with at least one WiFi antenna. 
Stacionarni modularni primopredajnik prema patentnom zahtjevu 8 pri čemu je barem jedna primopredajna antena Wi-Fi antena ili usmjerivač sa barem jednom Wi-Fi antenom.
Anti-Tack Agent Polysorbate 80 
Sredstvo protiv lijepljenja Polisorbat 80
• Muscarinic M3 receptor antagonists or anticholinergic agents 
antagonisti mišjeg M3-receptora ili antikolinergijska sredstva,
sterilizing the flaxseeds obtained in step (iii); and sprouting the sterilized flaxseeds. 
(iv) steriliziranje sjemenki lana dobivrnh u koraku (iii); i
or wherein R12 and R13 are taken together to form a 5-, 6-, or 7-membered unsubstituted or substituted heterocycle; 
* i pri čemu R i R1 se mogu uzeti zajedno tako da tvore (5-, 6-, ili 7-člani) heterocikal koji može biti nesupstituiran ili supstituiran;
A method for preparing an aqueous composition comprising aluminium, a reactive compound and a protein, wherein said method comprises 
Postupak za pripremu vodenog pripravka koja sadrži aluminij, reaktivni spoj i protein, pri čemu navedeni postupak sadrži
The apparatus according to claim 1 or 2, further comprising an implantable movement restriction device adapted to be implanted in connection with the fundus wall of the patient's stomach fundus wall, in a non-encircling manner with respect to the patient's stomach. The apparatus according to claim 3, wherein the movement restriction device adapted to be arranged such that a substantial part of the outer surface of the movement restriction device rests against the stomach wall in a position between the patient's diaphragm and at least a portion of the lower part of the invaginated stomach fundus wall, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted when the movement restriction device is invaginated, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, so as to maintain a supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što uređaj za rastezanje ima prvi međudjelujući element (10"; 110a; 210a; 410b), prilagođen za međudjelovanje s prvim dijelom stijenke želuca, i drugi međudjelujući element (10"; 110b; 210b; 410b), prilagođen za međudjelovanje s drugim dijelom stijenke želuca, blizu, no odvojen od prvog dijela želuca, gdje je uređaj za rukovanje prilagođen za rukovanje prvim i drugim međudjelujućim elementom kako bi ih se razmaknulo jednog od drugog, kada međudjelujući elementi međudjeluju s prvim i drugim dijelom želuca kako bi rastegnuli dio stijenke želuca između prvog i drugog dijela želuca, tako da se postigne privremeni osjećaj sitosti.
Transform-based decoder configured to decode a transform coefficient block using an apparatus (150) for decoding a significance map indicating positions of significant transform coefficients within the transform coefficient block from a data stream, according to any of claims 1 to 9, and to perform (152) a transform from spectral domain to spatial domain to the transform coefficient block. 
Dekoder na bazi transformacije, naznačen time, da je konfiguriran za dekodiranje bloka koeficijenata transformacije uporabom uređaja (150) za dekodiranje signifikacijske mape iz protoka podataka, koja prikazuje pozicije sigmifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, prema bilo kojem od zahtjeva 1 do 9, te za izvođenje (152) transformacije iz spektralne domene u prostornu domenu u bloku koeficijenata transformacije.
Genetic modification of human hepatoblast-like cells of the invention 
Datum objave europske prijave patenta:
The form of dabigatran, dabigatran etexilate, a prodrug of dabigatran or a pharmaceutically acceptable salt thereof may be in the form of a solid, liquid or gel. 
(b) farmaceutski sastav koji obuhvaća dabigatran, dabigatran-eteksilat, predlijek od dabigatrana ili njegovu farmaceutski prihvatljivu sol; (c) spremnik; i (d) etiketa.
The process according to claim 8, 9 or 10, wherein q is 1 and R5 is OCH3 at position 7 of the benzothiazepine ring, and the compound has the formula wherein M is hydrogen, ammonium, an alkali metal or an alkaline earth metal. 
Postupak u skladu s patentnim zahtjevom 8, 9 ili 10, naznačen time, da q je 1 i R5 je OCH3 na položaju 7 benzotiazepinskog prstena, a spoj ima formulu [image] pri čemu M je vodik, amonij, alkalijski metal ili zemnoalkalijski metal.
treating the textile with a cellulose solvent comprising an amine oxide to dissolve the cellulose at a temperature of 40-120 °C, for a duration of 1-90 minutes and with a cellulose concentration in the cellulose-containing liquid phase of 0.5-35 wt.%, separating a cellulose-containing liquid phase from the synthetic fibers, by decantation, centrifuge or filtration; and 
(a) tretiranja tekstila celuloznim otapalom koji sadrži aminoksid da bi se otopi celuloza na temperaturi od 40120 "C, u trajanju 1-90 minuta i s koncentracijom celuloze u tekućoj fazi koja sadrži celulozu od 0,5-35 wt.%, (b) odvajanje tekućoj faze koja sadrži celulozu od sintetičkih vlakana, dekantiranjem, centrifugiranjem ili filtracijom; i
The use according to claim 8, wherein the first sequence of 21, 22 or 23 nucleotides in the shRNA is complementary to a sequence that includes both a translated region and a portion of the 3' untranslated region (UTR) sequence in an mRNA molecule encoded by the gene, wherein the 3' UTR sequence in the mRNA molecule is present in the sequence of the target gene. 
shRNA prema patentnom zahtjevu 3, naznačena time, da je prvi slijed od 21, 22 ili 23 nukleotida komplementaran slijedu nukleotida koji uključuje i translatiranu regiju i dio slijeda 3' netranslatirane regije (UTR – untranslated region) molekule RNA kodirane genom, pri čemu je slijed 3' UTR u molekuli mRNA prisutan u slijedu ciljnog gena.
The guides 23 are preferably cylindrical in form and engage with the external base 22, running through it for a stretch, and exhibit a section with an enlarged diameter 27 that creates an annular groove 28 towards the outside, surrounding the guide stretch engaged in the plate. 
Poželjno je da vodilice 23 imaju cilindričan oblik 1 da su povezane s vanjskom bazom 22, prolazeći kroz nju za neku duljinu, i da imaju presjek s povećanim promjerom 27 koji stvara prstenasti utor 28 prema vanjskoj strani, i koji okružuje produženi dio vodilice koji je povezan s pločom.
Accordingly, the composition is preferably in the form of particles, such as pellets, spheroids or granules. 
Prema tome, pripravak je po mogućnosti u obliku čestica, poput peleta, sferoida ili granula.
The method of claim 1, wherein the cation exchange resin is regenerated in acid form, and/or wherein the anion exchange resin is regenerated in alkali form. 
pružanje smole za izmjenu kationa i smole za izmjenu aniona, pri čemu je smola za izmjenu kationa regenerirana u obliku kiseline, i pri čemu je smola za izmjenu aniona regenerirana u alkalnom obliku;
simulating in said loaded model a transition representative of said transition of said bottom hole assembly from stick mode to slip mode, 
simuliranje (33) assembly učitanom modelu tranzij+cije reprezentativne za tranziciju sklopa donje šupljine (11) iz stick načina do slip načina,
The compound for use according to claim 1, wherein tipifarnib is administered twice a day. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarnib primijenjen dva puta dnevno.
The compound or salt of claim 52 wherein said bullous skin disorder is pemphigus vulgaris (PV) or bullous pemphigoid (BP). 
Spoj ili sol prema zahtjevu 52 naznačen time da navedeni bulozni kožni poremećaj je pemfigus vulgaris (PV) ili bulozni pemfigoid (BP).
an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 213 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 220; 
(7) protutijelo koje sadržava varijabilnu regiju teškog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 214 (H78) i varijabilnu regiju lakog lanca koja sadržava aminokiselinski slijed SEQ ID NO: 220 (L17) (H78L17);
A kit of parts comprising (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 together with instructions for simultaneous, concurrent, separate or sequential use in combination with (a) a PDE4 inhibitor for the treatment of a patient suffering from or susceptible to a respiratory disease which responds to M3 antagonism. 
Komplet dijelova koji sadrži (b) antagonist M3 muskarinskih receptora kako je definirano u patentnom zahtjevu 1 ili 2 zajedno s uputama za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u kombinaciji s B2 agonistom kako je definirano u zahtjevu 1 ili 3, naznačen time, da je namijenjen za uporabu pri liječenju pacijenata koji pate od ili su podložni bolestima dišnih putova kako je definirano u zahtjevu 7 ili 8.
The pure isomers, enantiomers or diastereoisomers and their mixtures are within the scope of the present invention. 
Cisti izomeri, enantiomeri ili diastereoizomeri i njihove smjese su u opsegu smisla predloženog izuma.
Sample elution may also be achieved by the addition of mild organic modifiers or detergents to the elution buffer. 
Ispiranje uzorka također se može postići dodavanjem blagih organskih modifikatora ili deterđenata u pufer za ispiranje.
independently exposing the same parent bacterial strain as in step (a) comprising at least a portion of a CRISPR locus to the same bacteriophage as in step (a) to produce a mixture of bacteria comprising another bacteriophage resistant variant strain comprising a modified CRISPR locus comprising at least one additional spacer in said modified CRISPR locus; 
(b) neovisno izlaganje istog matičnog soja bakterije kao u koraku (a) koji sadrži barem dio CRISPR lokusa istom bakteriofagu kao u koraku (a) da se proizvede mješavina bakterija koja sadrži drugu varijantu soja rezistentnu na bakteriofage koja sadrži modificirani CRISPR lokus koji sadrži barem jednu dodatnu razmaknicu u navedenom modificiranom CRISPR lokusu;
a contiguous sequence of the human λ light chain locus that spans from Vλ3-29 to Vλ3-1 and a contiguous sequence of the human λ light chain locus that spans from Vλ5-52 to Vλ1-40. 
graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ5-52 do hVλ1-40 i graničnu sekvenciju humanog lokusa lakog λ lanca koja se proteže od hVλ3-29 do hVλ3-1.
A fluid distribution system according to claim 14 when dependent on claim 12, wherein said second fluid inlet to said pilot valve arrangement is fluidly connected to said intermediate line. 
Sustav (1000a) za distribuciju fluida prema zahtjevu 14 kada ovisi o zahtjevu 12, pri čemu je navedeni drugi dovod (122) fluida do navedenog sklopa (301, 1011a) pilot ventila fluidno povezan s navedenom srednjom linijom (1005a).
addition of aqueous solution of an active agent, 
dodavanja vodene otopine aktivnog sredstva,
Substituting sugar by the formulation as described in e.g. 
HR P20080437 T3 Zamjenom šećera formulacijom opisanom npr.
It may also be for use in the treatment of a patient known to have optic neuritis, myelitis and at least two of: MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO-IgG seropositivity According to a second aspect of the invention there is provided a pharmaceutical composition comprising 2-chloro-2′-deoxyadenosine, known as cladribine, for use in the treatment or amelioration of neuromyelitis optica. 
Pripravak, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 8 u liječenju ili ublažavanju NMO kod pacijenta za kojeg se zna da ima očni neuritis, mijelitis i najmanje dva MRI dokaza ozljeda 3 ili više uzastopnih segmenata kralježnične moždine po duljini, početni MRI mozga nedijagnostičan na multiplu sklerozu ili seropozitivnost na NMO-IgG.
The vessel was considered totally occluded by the thrombus formed when no blood flow was detected (0.0 ml/min). 
Žila se smatra potpuno začepljena nastalim trombom kad se dokaže da nema protoka krvi (0,0 ml/min).
Closure, particularly for closing construction and technological apertures 
ZATVARAČ, PRVENSTVENO ZA ZATVARANJE KONSTRUKCIJSKIH I TEHNOLOŠKIH OTVORA
In a variation, step a) is carried out in a first zone containing the first catalyst which occupies a volume V1, and step b) is carried out in a second zone containing the second catalyst which occupies a volume V2, the distribution of the volumes, V1/V2, being in the range 10% by volume/90% by volume to 50% by volume/50% by volume respectively for the first and second zone. 
Postupak prema jednom od zahtjeva 1 do 10, naznačen time da se korak a) provodi u prvoj zoni koja sadrži prvi katalizator koji zauzima volumen V1, te se korak b) provodi u drugog zoni koja sadrži drugi katalizator koji zauzima volumen V2, distribucija volumena, V1/V2, je u rasponu 10 volumenskih % /90 volumenskih % do 50 volumenskih % /50 volumenskih % redom za prvu i drugu zonu.
The mouse of claim 12, wherein: 
Miš u skladu s patentnim zahtjevom 1, naznačen time, da:
Alternatively, it can be added to the water to be purified in any appropriate solid form, e.g. in the form of granules or a powder or in the form of a cake. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je površinski-reagirani prirodni kalcij karbonat suspendiran u vodi koju treba pročistiti u obliku praha i/ili u obliku granula.
The dried granules were screened using U.S. Standard Sieve No. 30, 40, 50, and 80 mesh screens. 
Suhe granule se sortiraju sijanjem kroz U.S. standardna mrežasta sita broj 30, 40, 50 i 80.
Methods In one aspect, the present invention includes methods for detecting an antibody in a test sample. In certain embodiments, these methods relate, in pertinent part, to contacting the test sample with an Fc-binding molecule conjugated to a first detectable entity (i.e ., a detectable Fc-binding molecule-conjugate) to form a first complex, contacting the first complex with a capture entity immobilized on a test region of a surface, wherein the capture entity is capable of specifically binding to the antibody, and detecting the presence of a signal from the detectable Fc-binding molecule-conjugate in the test region. 
Postupak detektiranja prisutnosti protutijela u ispitivanom uzorku, naznačen time što se sastoji u: (a) stavljanje u kontakt ispitivanog uzorka s prvim detektorom i drugim detektorom kako bi se dobilo prvi kompleks, koji sadrži prvi detektor, drugi detektor, te protutijelo, gdje prvi detektor sadrži molekulu koja se veže na Fc, konjugiranu s prvim detektibilnim entitetom, gdje navedena molekula koja se veže na Fc se može specifično vezati na Fc područje protutijela, te gdje drugi detektor sadrži antigen ili antigeni peptid konjugiran s drugim detektibilnim entitetom, gdje se navedeni antigen ili antigeni peptid može specifično vezati na varijabilno područje protutijela;
The use according to any of claims 1 to 3, wherein the nucleic acid sequence coding for a plant pentose transporter comprises a nucleic acid sequence, which is at least 70% identical, preferably 80%, more preferably 90% identical to the nucleic acid sequence of SEQ ID NO: 2. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što nukleinskokiselinski slijed koji kodira biljni transporter pentoza sadrži nukleinskokiselinski slijed koji je najmanje 70% istovjetan, po mogućnosti 80%, poželjnije 90% istovjetan nukleinskokiselinskom slijedu SEQ ID NO: 2.
Number of subcultures FERM BP-10059 
Broj međunarodne prijave:
1H NMR analysis of the resultant dark oil revealed the residue to be a 1:14 mixture of ortho/para isomers. 
IH NMR analiza nastalog tamnog ulja otkrila je da je ostatak - 1:14 smjesa orto/para izomera.
and wherein the composition is substantially free of lipid, and wherein the composition forms a clear dispersion having a mean particle size of less than 1 µm upon dilution in simulated gastric fluid. 
dok je sastav uglavnom oslobođen od lipida, te pri čemu sastav tvori bistru disperziju koja ima glavnu veličinu čestica manju od 1 ^m nakon razrjeđivanja ili otapanja u simuliranoj želučanoj tekućini.
with an amino of formula (III): wherein R1 represents hydrogen or C1-4 alkyl group, R2 represents hydrogen or C1-4 alkyl group, and, where appropriate, separating the enantiomers and/or diastereomers, and/or cis- and/or trans-isomers of compounds of formula (I), or intermediates thereto, by conventional methods, and optionally thereafter forming salts and/or hydrates and/or solvates of the compound of formula (I). 
pri čemu predstavlja vodik ili C1-4 alkil skupinu, predstavlja vodik ili C1-4 alkil skupinu, i, gdje je prikladno, odvajanje enantiomera i/ili dijastereomera, i/ili cis- i/ili trans-izomera spojeva formule (I), ili njihovih intermedijera, konvencionalnim postupcima, te nakon toga, opcijski, oblikovanje soli i/ili hidrata i/ili solvata spoja formule (I).
The method of claim 1, wherein said inactivation is performed by addition of formaldehyde, or performed by UV irradiation. 
Postupak prema zahtjevu 1, naznačen time, da se spomenuto deaktiviranje provodi pomoću dodavanja formaldehida, ili se provodi pomoću UV zračenja.
The process according to the preceding claim, wherein the working fluid flow enters the turbo-expander (40) along an axial direction in a radially more internal zone of the turbo-expander (40) and exits, expanded, along a radial or axial direction in a radially more external zone of the turbo-expander (40). 
Postupak sukladno prethodnom zahtjevu pri čemu tok radne tekućine ulazi u turbo ekspander (40) duž aksijalnog smjera u radijalno više internoj zoni turbo ekspandera (40) i izlazi, ekspandirana, duž aksijalnog smjera u radijalno više eksternoj zoni turbo ekspandera (40).
The method according to claim 3, wherein the hematopoietic disorder/malignancy, the autoimmune disease and/or the inherited immunodeficient disease comprise bone marrow failure conditions, lupus, acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelodysplastic syndromes, multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, aplastic anemia, pure red cell aplasia, hemoglobinuria, Fanconi anemia, thalassemia, sickle cell anemia, Wiskott-Aldrich syndrome, or inborn errors of metabolism. 
Spoj kao što je definirano u patentnom zahtjevu 12 gdje navedeni hematopoetski poremećaj/malignitet, autoimuna bolest i/ili nasljedna imunodeficijentna bolest obuhvaćaju stanja insuficijencije koštane srži, razne kongenitalne bolesti općeg značaja (npr. anemiju srpastih stanica i talasemiju), lupus, akutnu mijeloidnu leukemiju, akutnu limfoblastnu leukemiju, kroničnu mijeloidnu leukemiju, kroničnu limfocitnu leukemiju, mijeloproliferativne poremećaje, mijelodisplastične sindrome, multipli mijelom, ne-Hodgkin-ov limfom, Hodgkin-ovu bolest, aplastičnu anemiju, čistu aplaziju eritrocita, hemoglobinuriju, Fanconi anemiju, talasemiju, anemiju srpastih stanica, Wiskott-Aldrich-ov sindrom, urođene greške u metabolizmu (kao što je Gaucher-ova bolest).